Ameritas Advisory Services LLC Sells 26,646 Shares of Pfizer Inc. $PFE

Key Points

• Ameritas Advisory Services LLC reduced its stake in Pfizer by 34.6%, selling 26,646 shares and retaining 50,311 shares, valued at approximately $1.22 million.
• Wall Street analysts have mixed views on Pfizer, with Bank of America raising their price target to $30 and Citigroup to $26, while the average target price sits at $28.41.
• Pfizer reported better-than-expected quarterly earnings, with $0.78 EPS and revenues of $14.65 billion, exceeding consensus estimates and showing a 10.3% year-over-year revenue increase.

Ameritas Advisory Services LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 34.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 50,311 shares of the biopharmaceutical company's stock after selling 26,646 shares during the period. Ameritas Advisory Services LLC's holdings in Pfizer were worth $1,220,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the first quarter valued at $27,000. North Capital Inc. purchased a new stake in Pfizer during the first quarter valued at $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer during the 1st quarter valued at about $28,000. Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the 1st quarter valued at about $35,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer during the 1st quarter valued at about $35,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent research reports. Bank of America upped their price objective on Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research note on Saturday, September 27th. Finally, UBS Group reissued a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $28.41.

Pfizer Stock Performance

PFE stock opened at $27.37 on Friday. The firm has a market cap of $155.59 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The business's fifty day simple moving average is $24.67 and its two-hundred day simple moving average is $24.14. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.